通过外部研究对随访伴侣诊断设备的药物有效性估计
Jiarui Sun1, Wenjie Hu1, Xiao-Hua Zhou1,2
1Beijing International Center for Mathematical Research, Peking University, Beijing, China.
Statistics in medicine
|November 6, 2024
概括
伴奏诊断设备 (CDx) 确保了针对性的治疗. 本研究引入了一种新的外部研究设计,用于验证后续的CDx设备,将现有试验数据与新的外部数据相结合,以改善患者分层.
科学领域:
- 生物标志物和诊断方法
- 临床试验设计 临床试验设计
- 个性化医疗是个性化的医疗.
背景情况:
- 治疗产品通常针对特定的患者亚群,需要伴随诊断设备 (CDx) 来识别患者.
- 首创的CDx通常通过随机试验开发并与治疗方法一起验证.
- 后续的CDx需要验证,但新的试验可能昂贵,不道德或不切实际.
研究的目的:
- 引入一种新的外部研究设计,用于验证后续伴随诊断设备 (FCD).
- 介绍统计分析方法来评估对比器 (CCD) 和后续 (FCD) 设备之间的一致性.
- 通过利用现有的临床试验数据,使FCD的间接验证成为可能.
主要方法:
- 提出了一种新的外部研究设计,即"向治疗设计",作为现有协同设计的扩展.
- 该方法将使用比较器CDx (CCD) 的随机试验数据与对后续CDx (FCD) 的外部研究数据集成在一起.
- 开发了统计分析方法,将这些数据源结合起来用于FCD验证.
主要成果:
- 提出的方法允许在FCD阳性 (FCD+) 和FCD阴性 (FCD-) 亚群中估计药物疗效.
- 这些估计是验证后续伴随诊断设备的性能和实用性的关键参数.
- 理论结果和模拟研究证明了拟议的统计方法的有效性.
结论:
- 针对性治疗设计提供了一种实用和道德的方法来验证后续伴随诊断设备.
- 这种方法有助于估计相关亚群的治疗效果,支持个性化医疗.
- 这种方法用在非小细胞肺癌中的现实应用来说明,证明了它的实用性.
相关概念视频
01:22Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
01:16Bioequivalence: Overview
926
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
926